|
ИСТИНА |
Войти в систему Регистрация |
ИПМех РАН |
||
SOLUBLE FORMS OF PD-1/PD-L IMMUNE CHECKPOINT RECEPTOR AND LIGAND IN BLOOD SERUM OF BREAST CANCER PATIENTS: ASSOCIATION WITH CLINICAL PATHOLOGIC FACTORS AND MOLECULAR TYPE OF THE TUMORстатья
Статья опубликована в журнале из списка RSCI Web of Science
Информация о цитировании статьи получена из
Scopus
Статья опубликована в журнале из перечня ВАК
Статья опубликована в журнале из списка Web of Science и/или Scopus
Дата последнего поиска статьи во внешних источниках: 26 июня 2024 г.
- Авторы: Gershtein Elena Sergeyevna, Korotkova E.A., Vorotnikov I.K., Sokolov N.Yu, Ermilova V.D., Mochalova A.S., Kushlinskii N.E.
- Журнал: Клиническая лабораторная диагностика
- Том: 67
- Номер: 2
- Год издания: 2022
- Издательство: Медицина
- Местоположение издательства: М.
- Первая страница: 76
- Последняя страница: 80
- DOI: 10.51620/0869-2084-2022-67-2-76-80
- Аннотация: Results of enzyme-linked immunosorbent assay of the soluble forms of PD-1/PD-L immune checkpoint receptor and ligand (sPD-1 and sPD-L1) in pretreatment blood serum of 88 breast cancer patients at various disease stages aged 30-83 years are presented. The control group included 55 practically healthy women aged 19-82 years. Serum sPD-1 and sPD-L1 levels in breast cancer patients highly significantly (p<0.0001) differ from control and these changes are opposite: soluble receptor level is more than 6-fold decreased, while soluble ligand concentration - 5.5 fold increased. Both markers separately, as well as their ratio demonstrate very high sensitivity (94-100%) and specificity (95-100%) in relation to healthy control. No statistically significant associations of sPD-1 and sPD-L1 levels with clinical stage, individual TNM system criteria, tumor histological structure, grade, receptor status, and molecular type were established. In particular, no significant peculiarities of the markers’ levels in triple negative breast cancer successfully treated with anti-PD-1/PD-L1 preparations were revealed. Long-term follow-up and dynamic studies of sPD-1 and sPD-L1serum levels in the course of treatment are required for evaluation of their independent from clinical and morphological factors prognostic significance and the possibility of application as low invasive tests for prediction and monitoring of corresponding targeted therapy efficiency.
- Добавил в систему: Воротников Игорь Константинович